Results 271 to 280 of about 1,944,084 (333)

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 867-884, May 2025.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano   +16 more
wiley   +1 more source

Cell Type-specific Regulation of B-Raf Kinase by cAMP and 14-3-3 Proteins [PDF]

open access: hybrid, 2000
W. Qiu   +4 more
openalex   +1 more source

Purification and characterization of a thermophilic NAD+‐dependent lactate dehydrogenase from Moorella thermoacetica

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 714-725, May 2025.
The thermophilic acetogenic model organism Moorella thermoacetica can utilize lactate as substrate. The formation of lactate by reduction of pyruvate is energetically favorable, but the reverse reaction, the oxidation of lactate to pyruvate with NAD+ as electron acceptor is challenging.
Florian P. Rosenbaum, Volker Müller
wiley   +1 more source

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 754-762, May 2025.
IDMF is a derivative of dimethyl fumarate (DMF) with a unique therapeutic potential at the intersection of psoriasis and multiple sclerosis. Here, we demonstrate that it compares favorably with DMF and its other derivatives, such as Diroximel, in the zebrafish, microglia, and lymphocyte models.
Yulin He   +5 more
wiley   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 836-855, May 2025.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy